Fagron (FAGR.BR) Stock Price
Fagron Price
Revenue has compounded at 6.7% per year over the past 19 years to 952.17 M EUR. Earnings per share have grown at 5.5% per year over the last 19 years. Fagron's net margin stands at 9.6%, down from 10.6% several years earlier. Fagron currently offers a dividend yield of about 1.57%. The payout ratio is around 28% of earnings. The dividend has grown at 11.4% per year over the past 17 years. Analysts set a median price target of 27.54 EUR, implying 23.5% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus.
Fagron stock price
Fagron business model & stock analysis
Frequently asked questions about Fagron
The business model of Fagron NV is focused on compounding and distributing personalized pharmaceutical products to pharmacies, hospitals, and clinics. Fagron operates as a global pharmaceutical company, supplying high-quality ingredients, equipment, and guidance to healthcare professionals. By providing tailor-made medicines, Fagron ensures that patients receive customized treatments that best suit their specific needs. Through its innovation-driven approach, Fagron collaborates with healthcare providers to improve patient outcomes and enhance the overall quality of pharmaceutical care. With a strong emphasis on compounding expertise and a wide range of product offerings, Fagron NV positions itself as a trusted partner in the pharmaceutical industry.
Fagron NV is primarily active in the pharmaceutical industry.
The main competitors of Fagron NV in the market are Teva Pharmaceutical Industries Ltd., Baxter International Inc., and McKesson Corporation.
Fagron NV, a renowned company in the stock market, has a rich history and background. Initially established in 1990, Fagron NV (previously known as Arseus NV) began its journey as a pharmaceutical wholesaler in Belgium. Over the years, the company evolved and expanded its focus towards compounding pharmacies globally, becoming a leading player in the compounding market. Fagron NV specializes in providing high-quality pharmaceutical ingredients, equipment, and innovative solutions to compounding professionals, enabling them to create tailored medications for their patients' unique needs. With a commitment to excellence and continuous growth, Fagron NV has become a trusted name in the pharmaceutical industry, offering comprehensive and reliable services worldwide.
Fagron NV has achieved several significant milestones in its history. The company has successfully expanded its global presence, becoming a leading player in the pharmaceutical compounding industry. Fagron NV has also demonstrated its commitment to innovation, developing advanced and personalized pharmaceutical solutions. Additionally, the company has achieved notable financial growth, consistently delivering strong financial performance over the years. Fagron NV's dedication to customer satisfaction and its continuous focus on quality have garnered it a solid reputation in the market. Overall, Fagron NV has a proven track record of success and remains at the forefront of the pharmaceutical industry.
Fagron NV is primarily present in a wide range of countries and regions across the globe. The company has a strong global presence, with operations in Europe, North America, South America, Asia-Pacific, and Africa. Fagron NV has established a strong foothold in various key markets, including the United States, Brazil, Belgium, the Netherlands, Germany, France, Spain, South Africa, and more. With its extensive international presence, Fagron NV is well-positioned to cater to the diverse needs of customers in different parts of the world while driving growth and innovation within the pharmaceutical compounding industry.
Fagron NV is a leading pharmaceutical company that values innovation, quality, and patient care. With a strong corporate philosophy, Fagron NV is committed to providing personalized medication solutions that meet the unique needs of patients worldwide. With a focus on research and development, Fagron NV strives to deliver high-quality compounded pharmaceuticals through advanced technology and expertise. By emphasizing patient well-being and professional collaboration, Fagron NV aims to improve the quality of life for individuals and contribute to the overall advancement of healthcare. Through its dedication to values and corporate philosophy, Fagron NV has become a trusted name in the pharmaceutical industry.
Analysts currently set an average price target of 27.18 EUR for the Fagron stock (median: 27.54 EUR), implying +21.9 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Fagron stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Fagron to generate revenue of 1.13 B EUR and earnings per share of 1.45 EUR.
The Fagron share (FAGR.BR) is listed on 6 stock exchanges, including: London (0HNZ.L), Frankfurt (4A5.F), Düsseldorf (4A5.DU).
Fagron NV is an internationally operating company specializing in the production and distribution of pharmaceutical products and services. The company operates worldwide in over 30 countries and is based in the Netherlands.
The expected revenue of Fagron is 1.13 B EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Fagron is 106.07 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Fagron is currently 15.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fagron stock.
The price-to-sales ratio (P/S) of Fagron is currently 1.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fagron stock.
The Eulerpool Quality Score for Fagron is 7/10.
The ISIN of Fagron is BE0003874915. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Fagron is A0M103. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Fagron is FAGR.BR. The ticker symbol is used to trade Fagron shares on the stock exchange.
Fagron stock
Fagron Peer Group
Fagron Ticker
Fagron FIGI
All fundamentals and in-depth analysis of Fagron
Our stock analysis for Fagron stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fagron. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.